First Time Loading...

Selecta Biosciences Inc
NASDAQ:SELB

Watchlist Manager
Selecta Biosciences Inc Logo
Selecta Biosciences Inc
NASDAQ:SELB
Watchlist
Price: 0.7465 USD 5.14%
Updated: Apr 18, 2024

Intrinsic Value

SELB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention... [ Read More ]

The intrinsic value of one SELB stock under the Base Case scenario is 1.0582 USD. Compared to the current market price of 0.7465 USD, Selecta Biosciences Inc is Undervalued by 29%.

Key Points:
SELB Intrinsic Value
Base Case
1.0582 USD
Undervaluation 29%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Selecta Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SELB stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Selecta Biosciences Inc

Provide an overview of the primary business activities
of Selecta Biosciences Inc.

What unique competitive advantages
does Selecta Biosciences Inc hold over its rivals?

What risks and challenges
does Selecta Biosciences Inc face in the near future?

Has there been any significant insider trading activity
in Selecta Biosciences Inc recently?

Summarize the latest earnings call
of Selecta Biosciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Selecta Biosciences Inc.

Provide P/S
for Selecta Biosciences Inc.

Provide P/E
for Selecta Biosciences Inc.

Provide P/OCF
for Selecta Biosciences Inc.

Provide P/FCFE
for Selecta Biosciences Inc.

Provide P/B
for Selecta Biosciences Inc.

Provide EV/S
for Selecta Biosciences Inc.

Provide EV/GP
for Selecta Biosciences Inc.

Provide EV/EBITDA
for Selecta Biosciences Inc.

Provide EV/EBIT
for Selecta Biosciences Inc.

Provide EV/OCF
for Selecta Biosciences Inc.

Provide EV/FCFF
for Selecta Biosciences Inc.

Provide EV/IC
for Selecta Biosciences Inc.

Show me price targets
for Selecta Biosciences Inc made by professional analysts.

What are the Revenue projections
for Selecta Biosciences Inc?

How accurate were the past Revenue estimates
for Selecta Biosciences Inc?

What are the Net Income projections
for Selecta Biosciences Inc?

How accurate were the past Net Income estimates
for Selecta Biosciences Inc?

What are the EPS projections
for Selecta Biosciences Inc?

How accurate were the past EPS estimates
for Selecta Biosciences Inc?

What are the EBIT projections
for Selecta Biosciences Inc?

How accurate were the past EBIT estimates
for Selecta Biosciences Inc?

Compare the revenue forecasts
for Selecta Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Selecta Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Selecta Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Selecta Biosciences Inc compared to its peers.

Compare the P/E ratios
of Selecta Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Selecta Biosciences Inc with its peers.

Analyze the financial leverage
of Selecta Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Selecta Biosciences Inc.

Provide ROE
for Selecta Biosciences Inc.

Provide ROA
for Selecta Biosciences Inc.

Provide ROIC
for Selecta Biosciences Inc.

Provide ROCE
for Selecta Biosciences Inc.

Provide Gross Margin
for Selecta Biosciences Inc.

Provide Operating Margin
for Selecta Biosciences Inc.

Provide Net Margin
for Selecta Biosciences Inc.

Provide FCF Margin
for Selecta Biosciences Inc.

Show all solvency ratios
for Selecta Biosciences Inc.

Provide D/E Ratio
for Selecta Biosciences Inc.

Provide D/A Ratio
for Selecta Biosciences Inc.

Provide Interest Coverage Ratio
for Selecta Biosciences Inc.

Provide Altman Z-Score Ratio
for Selecta Biosciences Inc.

Provide Quick Ratio
for Selecta Biosciences Inc.

Provide Current Ratio
for Selecta Biosciences Inc.

Provide Cash Ratio
for Selecta Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Selecta Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Selecta Biosciences Inc?

What is the current Free Cash Flow
of Selecta Biosciences Inc?

Financials

Balance Sheet Decomposition
Selecta Biosciences Inc

Current Assets 122.7m
Cash & Short-Term Investments 112m
Receivables 6.4m
Other Current Assets 4.3m
Non-Current Assets 16.8m
Long-Term Investments 2m
PP&E 13.4m
Other Non-Current Assets 1.4m
Current Liabilities 29.4m
Accounts Payable 267k
Accrued Liabilities 14.6m
Other Current Liabilities 14.5m
Non-Current Liabilities 44.7m
Long-Term Debt 13.8m
Other Non-Current Liabilities 30.9m
Efficiency

Earnings Waterfall
Selecta Biosciences Inc

Revenue
48.7m USD
Operating Expenses
-95.8m USD
Operating Income
-47.1m USD
Other Expenses
12.1m USD
Net Income
-35.1m USD

Free Cash Flow Analysis
Selecta Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

SELB Profitability Score
Profitability Due Diligence

Selecta Biosciences Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Years Revenue Growth
ROIC is Increasing
Negative 1-Year Revenue Growth
36/100
Profitability
Score

Selecta Biosciences Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

SELB Solvency Score
Solvency Due Diligence

Selecta Biosciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
50/100
Solvency
Score

Selecta Biosciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SELB Price Targets Summary
Selecta Biosciences Inc

There are no price targets for SELB.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SELB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SELB Price
Selecta Biosciences Inc

1M 1M
-
6M 6M
-35%
1Y 1Y
-39%
3Y 3Y
-80%
5Y 5Y
-68%
10Y 10Y
-95%
Annual Price Range
0.7465
52w Low
0.67
52w High
1.4
Price Metrics
Average Annual Return 13.57%
Standard Deviation of Annual Returns 15.2%
Max Drawdown -87%
Shares Statistics
Market Capitalization 114.5m USD
Shares Outstanding 153 427 008
Percentage of Shares Shorted 7.8%

SELB Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Selecta Biosciences Inc Logo
Selecta Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

114.5m USD

Dividend Yield

0%

Description

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2016-06-22. The firm leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The company enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.

Contact

MASSACHUSETTS
Watertown
65 Grove Street
+16179231400.0
http://selectabio.com/

IPO

2016-06-22

Employees

58

Officers

See Also

Discover More
What is the Intrinsic Value of one SELB stock?

The intrinsic value of one SELB stock under the Base Case scenario is 1.0582 USD.

Is SELB stock undervalued or overvalued?

Compared to the current market price of 0.7465 USD, Selecta Biosciences Inc is Undervalued by 29%.